Skip to main content

Table 11 Hazard ratios (CCLG vs. GPOH) according to local treatment modality, among patients with metastatic disease only

From: Survival is influenced by approaches to local treatment of Ewing sarcoma within an international randomised controlled trial: analysis of EICESS-92

  Local treatment modality
Radiotherapy (RT) alone
N = 56
Surgery alone
N = 19
RT and surgery
N = 66
No. events
 EFS 43 11 48
 OS 39 8 43
Unadjusted
 EFS 0.79 (0.43–1.44) 0.79 (0.24–2.61) 2.01 (0.89–4.54)
 OS 0.92 (0.49–1.74) 0.71 (0.18–2.85) 1.98 (0.88–4.47)
Adjusted for age, primary site, histology and time between the start of chemotherapy and starting local treatment
 EFS 0.81 (0.44–1.67) Too few patients to allow for other factors reliably 2.51 (0.89–7.06)
 OS 1.01 (0.50–2.01) 2.54 (0.90–7.20)
  1. Hazard ratios greater than 1 indicate that CCLG patients had a higher risk of having an event or dying compared to GPOH patients
  2. Based on data excluding patients with unknown primary site because there were so few
  3. EFS event-free survival; OS overall survival